Pfizer dials down its atirmociclib ambitions
The company is stepping back in second-line breast cancer.
A pivotal push from BeiGene
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Pfizer moves pivotal assets into the front line
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
ESMO 2024 – combos could be the way forward for CDK2
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
